Moderator: Paula J. Anastasia RN, MN, AOCN Gyn-Onc Clinical Nurse Specialist Cedars-Sinai Medical Center Los Angeles, CA
|
|
- Hubert Day
- 5 years ago
- Views:
Transcription
1
2 Disclaimer This slide deck in its original and unaltered format is for educational purposes and is current as of May The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Creative Educational Concepts or the supporter. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.
3 Usage Rights This slide deck is provided for educational purposes and slides may be used for personal, non-commercial presentations only as long as content and references remain the same. No part of this slide deck may be published or distributed in print or electronic format without prior written permission from Creative Educational Concepts.
4
5 Moderator: Paula J. Anastasia RN, MN, AOCN Gyn-Onc Clinical Nurse Specialist Cedars-Sinai Medical Center Los Angeles, CA
6 Optimizing DNA Damage Response Targeting Therapies: Focus on Genetic Testing and Counseling Nadine M. Tung, MD Beth Israel Deaconess Medical Center Boston, MA
7 Genetic Testing and Counseling Who should get genetic testing? Which genes should be tested? How does this impact treatment?
8 Who Should be Tested for BRCA1/2 Mutations? BRCA1/2 mutations increase the risk for: Breast cancer EOC/FT/PPC Pancreatic cancer Prostate cancer BRCA2 more aggressive: Gleason score >7, higher stage, more risk metastatic disease BRCA2: Melanoma, biliary?/gastric? not part of criteria for testing NCCN Breast/Ovarian Genetic Assessment Guidelines Version
9 Who Should be Tested for BRCA1/2 Mutations? Ovarian Cancer All EOC/FT/PPC pts NCCN, ASCO, SGO agree Insurance cover appropriate pts NCCN Breast/Ovarian Genetic Assessment Guidelines Version ;
10 Who Should be Tested for BRCA1/2 Mutations? Breast Cancer 45 yrs ( 50 yrs if small family/few women) TNBC 60 yrs Ashkenazi Jewish ancestry Male Bilateral 1 st 50 yrs 50 yrs: 1 relative with breast, pancreatic, or prostate cancer Any age: 2 relatives with breast, pancreatic, or prostate cancer 1 relative with ovarian cancer 1 relative with breast cancer diagnosed 50 yrs 1 male relative with breast cancer NCCN Breast/Ovarian Genetic Assessment Guidelines Version
11 Who Should be Tested for BRCA1/2 Mutations? Other Cancers Pancreatic or prostate cancer (Gleason score 7): 1 relative: breast 50 yrs or ovarian cancer (any age) 2 relatives: breast (any age), pancreatic, or prostate cancer Ashkenazi Jewish pancreatic cancer Family hx of BRCA1/2 mutation Somatic BRCA1/2 mutation identified in tumor NCCN Breast/Ovarian Genetic Assessment Guidelines Version
12 Incidence of BRCA1/2 Germline (Inherited) Mutations Breast Cancer: 3-4% (Overall) 10-20% (TNBC) 10-15% (Ashkenazi Jewish breast cancer) Ovarian Cancer: 15% Gonzalez-Angulo AM, et al. Clin Cancer Res. 2011; Sharma P, et al. Breast Cancer Res Treat. 2014; Rummel S, et al. Breast Cancer Res Treat. 2013; Warner E, et al. J Natl Cancer Inst. 1999; King MC, et al. Science. 2003; Risch HA, et al. J Natl Cancer Inst. 2006; Norquist BM, et al. JAMA Oncol
13 Incidence of BRCA1/2 Germline (Inherited) Mutations Pancreatic Cancer 1-5% (Overall) 12% (Ashkenazi Jewish pancreatic cancer) Prostate Cancer 1-2% (Overall) Metastatic: 6% (BRCA2 5%; BRCA1 1%) Holter S, et al. J Clin Oncol. 2015; Agalliu I, et al. Clin Cancer Res. 2009; Prichard CC, et al. N Engl J Med
14 BRCA1/2 Repair Double Strand Breaks in DNA: Homologous Recombination Pennington KP, et al. Gynecol Oncol
15 Criteria for Panel Testing and Types of Panel Testing No criteria or predictors for mutations in more moderate risk genes Multi-gene panels High risk genes (>5x risk cancer) vs. high and moderate risk (2-5x risk cancer) By cancer type or all cancers Tung N, et al. Nat Rev Clin Oncol
16 Breast/Ovarian Cancer Risks with Novel Genes Gene Breast Ovary PALB2 Y (RR 5.3)? (RR ) ATM Y (RR 2.8) CHEK2 (truncating) Y (RR 3.0) NBN Y (RR 2.7) NF1 Y (RR 2.6) BRIP1 Y (RR ) RAD51C Y (OR 5.2) RAD51D Y (OR 12) Easton DF, et al. N Engl J Med. 2015; Antoniou AC, et al. N Engl J Med. 2014; Norquist BM, et al. JAMA Oncol. 2015; Ramus SJ, et al. J Natl Cancer Inst. 2015; Song H, et al. J Clin Oncol
17 Risk of Breast Cancer Associated with Inherited Mutations Gene Breast Cancer Risk (by age 70) High Penetrance BRCA % BRCA % PALB % Moderate Penetrance ATM 20-30% CHEK % Antoniou AC, et al. N Engl J Med. 2014; Tung N, et al. Nat Rev Clin Oncol. 2016; Graffeo R, et al. Breast Cancer Res Treat
18 Management Guidelines for BRCA1/2 Carriers Screening Clinical breast exam Breast MRI Mammogram Management Option Transvaginal US, CA 125 Prevention Bilateral mastectomy Screening Interval/Comment Q6-12 months beginning age 25 Annually: Begin age 25 Annually: Begin age 30 Insufficient data to recommend; may consider starting age Discuss degree of protection, reconstruction options and risks Bilateral salpingo-oophorectomy BRCA1: age 35-40; BRCA2: by age 45 Consider OCP Consider tamoxifen, raloxifene, or AI NCCN Breast/Ovarian Genetic Assessment Guidelines Version ; Visvanathan K, et al. J Clin Oncol
19 NCCN Guidelines Version Breast/Ovarian Management Based on Genetic Test Results Gene Intervention warranted based on gene and/or risk level Recommended Breast MRI (>20% risk of breast cancer) ATM BRCA1 BRCA2 CDH1 CHEK2 NBN NF1 PALB2 PTEN TP53 Discuss Option of RRM BRCA1 BRCA2 CDH1 PTEN TP53 PALB2* *Consider based on family history NCCN Breast/Ovarian Genetic Assessment Guidelines Version
20 Risk of Ovarian Cancer Gene Estimated Lifetime Risk of Ovarian Cancer Recommended Age for RRSO BRCA % BRCA % By age 45 BRIP1 13% (or lower?) >45 RAD51C 6% >45 RAD51D 14% >45 PALB %?? Unknown or insufficient evidence NCCN Breast/Ovarian Genetic Assessment Guidelines Version ; Hartmann LC, et al. N Engl J Med. 2016; Antoniou AC, et al. N Engl J Med. 2014; Norquist BM, et al. JAMA Oncol. 2015; Ramus SJ, et al. J Natl Cancer Inst. 2015; Song H, et al. J Clin Oncol. 2015; Chen S. Parmigiani G. J Clin Oncol. 2007; Mavaddat N, et al. J Natl Cancer Inst
21 Why Do Genetic Testing of a Cancer Patient? Family members Identify other cancers to screen for/or prevent Treatment Platinum PARP inhibitors
22 The Development of Hereditary Cancer 1 damaged gene 1 normal gene All cells in the body: One functioning BRCA gene 2 damaged genes Cancer cells: No functioning BRCA gene Tumor Develops
23 Platinum Damage DS DNA Break Evans MK, Longo DL. N Engl J Med
24 Platinum is Effective in Cancers in Patients with BRCA1/2 Mutations Platinum causes more DS DNA breaks Cancers without BRCA1 or BRCA2 can t repair these breaks Ovarian cancer patients with BRCA1/2 mutations have a better prognosis In part due to higher sensitivity to platinum BRCA1/2 breast cancer Platinum is effective but less data (most info is for TNBC) Still being studied Evans MK, Longo DL. N Engl J Med. 2014;
25 Why Do Genetic Testing of a Cancer Patient? Family members Identify other cancers to screen for or prevent Treatment Platinum PARP inhibitors
26 Platinum Damage SS DNA Break DS DNA Break Evans MK, Longo DL. N Engl J Med
27 PARP Inhibitors: Synthetic Lethality in BRCA Breast Cancers Inglehart JD, Silver DP. N Engl J Med
28 PARP Inhibition: A Possible Achilles Heel for Solid Tumors? BJ Rimel, MD Cedars-Sinai Medical Center Los Angeles, CA
29 What is PARP? Poly (ADP-Ribose) Polymerase Single Strand Break PARP Unrepaired double strand breaks lead Double Strand Break from radiation or to CELL DEATH!!! chemotherapy Morales J, et al. Crit Rev Eukaryot Gene Expr
30 Olaparib DNA AZ1775 Inactive Mitosis Active Rationale for PARP inhibition: antiangiogenesis and cell cycle inhibition Cediranib Ivy SP, et al. Expert Opin Investig Drugs. 2016; Matheson CJ, et al. Trends Pharmacol Sci
31 Olaparib DNA AZ1775 Inactive Mitosis Active Rationale for PARP inhibition: antiangiogenesis and cell cycle inhibition Cediranib Ivy SP, et al. Expert Opin Investig Drugs. 2016; Matheson CJ, et al. Trends Pharmacol Sci
32 Olaparib DNA AZ1775 Inactive Mitosis Active Rationale for PARP inhibition: antiangiogenesis and cell cycle inhibition Cediranib Ivy SP, et al. Expert Opin Investig Drugs. 2016; Matheson CJ, et al. Trends Pharmacol Sci
33 Olaparib DNA AZ1775 Inactive Mitosis Active Rationale for PARP inhibition: antiangiogenesis and cell cycle inhibition Cediranib Ivy SP, et al. Expert Opin Investig Drugs. 2016; Matheson CJ, et al. Trends Pharmacol Sci
34 Currently Approved PARP Inhibitors Olaparib Rucaparib Niraparib
35 PARP Inhibitors in Clinical Trials Veliparib Talazoparib
36 Olaparib On December 19, 2014, the US Food and Drug Administration (FDA) approved olaparib capsules as monotherapy for the treatment of patients with deleterious or suspected deleterious germline BRCA mutated (gbrcam) (as detected by an FDAapproved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy. Concurrent with this action, FDA approved a multiplex PCR companion diagnostic test for the qualitative detection and classification of variants in the BRCA1 and BRCA2 genes. FDA Prescribing Information;
37 Olaparib Indication Olaparib is approved for women with a germline BRCA mutation After failing three prior lines of therapy for ovarian cancer Has a companion diagnostic test, which is a blood test for the presence of a germline BRCA 1 or 2 mutation 400 mg twice daily (16 capsules) FDA Prescribing Information.
38 Olaparib Study 19 Randomized phase II, double blind study of recurrent platinum-sensitive serous ovarian cancer Two prior lines of platinum required with complete or partial response to the prior line of platinum 265 women randomized N=136 (olaparib) N=129 (placebo) 136 patients had deleterious BRCA mutation 400 mg twice daily (16 capsules) Ledermann JA, et al. N Engl J Med. 2012; Ledermann JA, et al. Lancet Oncol
39 Probability of Progression- Free Survival PFS in Randomized Population No. at Risk Olaparib Placebo Olaparib Placebo Months since Randomization Hazard ratio, 0.35 (95% CI, ) P< HUGE difference in PFS No. of Patients/ Median Progressionfree Survival (mo) Total No. (%) 60/136 (44.1) /129 (72.1) 4.8 Adapted from Ledermann JA, et al. N Engl J Med
40 Subgroup Analysis of PFS in Randomized Population Ledermann JA, et al. N Engl J Med
41 Progression-Free Survival (Proportion) Olaparib in Germline BRCA Mutation Tumors Ovarian (median, 7.0 months) Breast (median, 3.7 months) Pancreas (median, 4.6 months) Prostate (median, 7.2 months) Germline BRCA mutation carriers Tumor agnostic Median PFS in ovarian cancer: 7 months 0.2 No. at risk Ovarian Breast Pancreas Prostate Time From First Dose (months) Adapted from Kaufmann B, et al. J Clin Oncol
42 Overall Survival (%) Olaparib in gbrca and BRCAwt Overall Survival Olaparib Placebo Deaths/total patients (%) Median OS, months (95% CI) HR 0.73 (95% CI ); P=.025 Olaparib Placebo 94/136 (69%) 109/129 (84%) 29.8 ( ) 27.8 ( ) All patients randomized (N=265) Did not reach pre-specified statistical significance. Number at Risk Olaparib Placebo (0) 129 (5) 117 (2) 97 (2) 79 (0) 62 (0) 52 (0) 43 (0) 42 (0) 41 (0) 37 (0) 35 (0) 15 (19) 2 (12) 0 (2) 129 (0) 122 (3) 112 (1) 90 (0) 75 (1) 57 (0) 44 (0) 37 (0) 32 (0) 27 (0) 24 (1) 18 (0) 9 (5) 1 (8) 0 (1) Adapted from Ledermann JA, et al. Lancet Oncol
43 Overall Survival (%) Olaparib in gbrca Overall Survival Olaparib Placebo Deaths/total patients(%) Median OS, months (95% CI) HR 0.62 (95% CI ); P=.025 Olaparib Placebo 47/74 (64%) 48/62 (77%) 34.9 ( ) 30.2 ( ) Germline BRCA mutated N=136 Did not reach pre-specified statistical significance. Number at Risk Olaparib Placebo (0) 69 (4) 65 (0) 56 (2) 50 (0) 39 (0) 33 (0) 27 (0) 27 (0) 27 (0) 25 (0) 23 (0) 11 (11) 1 (9) 0 (1) 62 (0) 58 (2) 52 (1) 40 (0) 34 (1) 29 (0) 25 (0) 20 (0) 19 (0) 15 (0) 13 (1) 10 (0) 6 (3) 0 (6) 0 (0) Adapted from Ledermann JA, et al. Lancet Oncol
44 Rucaparib On December 19, 2016, the US Food and Drug Administration granted accelerated approval to rucaparib for treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies. Concurrent with this action, the FDA approved a next generation sequencing-based companion diagnostic test for use with rucaparib to detect the presence of deleterious mutations.
45 Rucaparib Indication At least two prior lines of therapy Germline BRCA mutation OR somatic BRCA mutation (tumor specific mutation, methylation or protein loss) 600 mg twice daily (4 tablets) FDA Prescribing Information.
46 Rucaparib ARIEL2 Phase II study of recurrent platinum-sensitive high grade serous ovarian cancer At least one prior platinum therapy 3 pre-specified groups: BRCA mutant (germline or somatic) BRCAwt LOH high BRCAwt LOH low Enrolled N=206 Swisher EM, et al. Lancet Oncol
47 Progression-free Survival Rucaparib in gbrca and BRCAwt PFS BRCA mutant vs. BRCA wild-type and LOH low: HR 0.27 (95% CI ); P<.001 BRCA wild-type and LOH high vs. BRCA wild-type and LOH low: HR 0.62 (95% CI ); P= BRCA mutant BRCA wild-type and LOH high BRCA wild-type and LOH low Number at Risk (number censored) BRCA mutant BRCA wild-type and LOH high BRCA wild-type and LOH low 0 0 Adapted from Swisher EM, et al. Lancet Oncol Time from Start of Treatment (months) 45 (0) 40 (0) 39 (0) 39 (0) 36 (0) 36 (0) 34 (0) 33 (1) 27 (3) 25 (4) 22 (4) 20 (5) 29 (4) 16 (6) 12 (9) 9 (10) 7 (10) 5 (12) 5 (12) 5 (12) 2 (15) 2 (15) 0 (16) 82 (0) 77 (3) 61 (8) 56 (9) 48 (9) 45 (11) 36 (11) 31 (14) 27 (14) 23 (14) 21 (15) 20 (15) 18 (15) 17 (15) 14 (18) 10 (21) 5 (23) 4 (23) 3 (24) 1 (25) 1 (25) 70 (0) 69 (1) 53 (2) 48 (5) 37 (5) 34 (6) 23 (7) 22 (7) 15 (8) 14 (8) 12 (8) 10 (9) 6 (9) 4 (10) 3 (10) 2 (10) 1 (10) 0 (10)
48 Niraparib On March 27, 2017, the US Food and Drug Administration approved niraparib, a poly ADP-ribose polymerase (PARP) inhibitor, for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.
49 Niraparib Indication Maintenance treatment Recurrent ovarian cancer Complete or partial response to platinum chemotherapy 300 mg once daily (3 tablets) FDA Prescribing Information.
50 Niraparib NOVA Randomized, double blind, placebo controlled phase III trial Platinum sensitive epithelial ovarian cancer (majority high grade serous) At least two prior platinum regimens Examination for homologous recombination deficiency (HRD) Randomized 2:1 Enrolled N= gbrca 350 BRCAwt Mirza MR, et al. N Engl J Med
51 Niraparib in gbrca PFS Mirza MR, et al. N Engl J Med
52 Niraparib in non-gbrca with and without HRD Positivity PFS No Germline BRCA Mutation with HRD Positivity No Germline BRCA Mutation Mirza MR, et al. N Engl J Med
53 Selected Toxicity Grade 3 Nausea Vomiting Constipation Anemia Thrombocytopenia Fatigue Olaparib 1 0.5% 2.6% <5% 18.7% <5% 6.2% Rucaparib 2 4% 2% 1% 21% 2% 9% Niraparib 3 3% 1.9% 0.5% 25.3% 33.8% 8.2% 1 Kaufmann B, et al. J Clin Oncol. 2015; 2 Swisher EM, et al. Lancet Oncol. 2017; 3 Mirza MR, et al. N Engl J Med
54 PARPi Response Rates and Toxicities BRCA1/2 Mutant BRCA1/2 Wild Type and Unknown Drug No. Response No. Response Olaparib Rucaparib >100 (mostly platinum resistant) 39 (all platinum sensitive) 30-60% 46 69% 132 Platinum sensitive 50% Platinum resistant 4% LOH high 29% LOH low 13% Predominant toxicity (in order of frequency) GI symptoms, fatigue, anemia GI symptoms, fatigue, anemia, transient ALT/AST elevations Niraparib 20 (9 platinum sensitive) 40% 3 19 Platinum sensitive 67% Platinum resistant 16% Anemia, thrombocytopenia, neutropenia, GI symptoms, fatigue Talazoparib 26 a 46% - - Fatigue, alopecia, GI symptoms, anemia, neutropenia, thrombocytopenia Veliparib 28 a,b 40% 24 a,b 4% Nausea, fatigue, lymphopenia a Platinum responsiveness not known b Includes triple negative breast cancer Brown JS, et al. Br J Cancer
55 PARP Inhibitors in BRCA+ Breast Cancer Nadine M. Tung, MD Beth Israel Deaconess Medical Center Boston, MA
56 PARP Inhibitors: Women with gbrca+ Breast Cancer (Iceberg Trial: Olaparib) 27 metastatic BRCA+ breast cancer at 400 mg twice daily Many patients heavily pre-treated 41% RR 85% responded or had stable disease Responses seen in ER+ and ER-neg (TNBC) Well tolerated, oral therapy Tutt A, et al. Lancet. 2010; Audeh MW, et al. Lancet
57 Randomized PARP Inhibitor Studies in Metastatic Breast Cancer: BRCA1/2 gbrca+ metastatic disease Anthracycline, taxane resistant Randomized PARP inhibitor daily Standard Chemo, MD s choice: Primary Endpoint: PFS BRAVO Trial (NCT ) - Niraparib EMBRACA (NCT ) - Talazoparib OLYMPIAD Trial (NCT ) - Olaparib Capecitabine or Vinorelbine or Eribulin or Gemcitabine
58 Randomized PARP Inhibitor Studies in Metastatic Breast Cancer: BRCA1/2 gbrca+ metastatic disease Anthracycline, taxane resistant BRAVO Trial (NCT ) - Niraparib EMBRACA (NCT ) Talazoparib OLYMPIAD Trial (NCT ) - Olaparib Randomized PARP inhibitor daily OlympiAD Trial: Standard Chemo, MD s choice: Positive : Increased PFS for olaparib vs chemotherapy Capecitabine or Vinorelbine or Eribulin or Gemcitabine Results: ASCO Primary Endpoint: PFS
59 Olaparib in Adjuvant Breast Cancer Setting: OlympiA gbrca+ TNBC or ER+ I. Adjuvant: T2 or N+ II. Neoadjuvant: Residual disease Randomized After chemo and surgery PARP inhibitor daily X 1 yr Placebo X 1 yr Endpoints: DFS DDFS OS NCT
60 Efficacy of PARP Inhibitors may be Lower in Breast Cancer pts with Prior Platinum Study 42: Study of various gbrca+ cancers 62 breast cancer pts 3 prior chemo in metastatic setting ORR 12.9% Response rate differed if prior platinum (20% vs. 9.5%) Kaufman B, et al. J Clin Oncol
61 Reversion Mutations have been described in BRCA+ breast cancers after platinum The new mutation restores the BRCA1 or BRCA2 function in the cancer cell So PARP inhibitor may not work Afghahi A, et al. Clin Cancer Res
62 Select Studies Combining PARPi with Platinum Chemotherapy BROCADE (NCT ) Paclitaxel/carboplatin vs. paclitaxel/carboplatin/veliparib vs. veliparib/temozolomide gbrca+ metastatic breast cancer Study 21 1 (NCT ) Cisplatin/olaparib Advanced solid tumors Carboplatin/olaparib 2 (NCT ) BRCA+ advanced breast, ovarian cancer 1 Balmaña J, et al. Ann Oncol. 2014; 2 Lee JM, et al. J Natl Cancer Inst
63 Hard to Combine Chemo and PARPi Myelosuppression limit dose chemo and PARPi
64 PARP Inhibitors in Additional Solid Tumors
65 Ongoing PARPi Trials in Pancreatic Cancer Trial Phase Treatment Arms Inclusion Primary Outcomes NCT II Olaparib Non-gBRCA1/2 mutation or HRD deficiency NCT II Olaparib Non-gBRCA1/2 mutation ORR POLO NCT III Olaparib Placebo gbrca1/2 mutation NCT I/II Veliparib/mFOLFOX BRCA1/2 mutation NCT NCT II II Veliparib Veliparib/gemcitabine/ cisplatin Gemcitabine/cisplatin Veliparib/FOLFIRI FOLFIRI BRCA1/2 or PALB2 mutation Metastatic pancreatic cancer ORR PFS Dose limiting toxicities ORR FOLFIRI: Fluorouracil, irinotecan, leucovorin; mfolfox: Modified 5-fluorouracil and oxaplatin OS
66 Ongoing PARPi Trials in Prostate Cancer Trial Phase Treatment Arms Inclusion PROfound NCT III Olaparib Enzalutamide Abiraterone NCT II Olaparib TRITON3 NCT TRITON2 NCT GALAHAD NCT NCT III II II II Rucaparib Enzalutamide Abiraterone Docetaxel Rucaparib Niraparib Veliparib/abiraterone Abiraterone mcrpc, progression on androgen receptor targeted therapy HRR deficiency in tumor tissue Malignant solid tumor (including prostate) gbrca1/2 mcrpc, progression on androgen receptor targeted therapy BRCA1/2 or ATM mutation mcrpc, progression on 1 androgen receptor targeted therapy and 1 taxane BRCA1/2, ATM or other HR deficiency mcrpc, progression on >1 taxane and >1 androgen receptor targeted therapy Tumor w/ DNA repair anomalies mcrpc, progression on androgen deprivation therapy Primary Outcomes rpfs Tumor response rate rpfs ORR PSA response ORR PSA response
67 Improving Patient Outcomes with PARP Inhibitors: Case-based Treatment Strategies for the Oncology Nurse Lisa Arvine, RN, MSN, ANP-BC, WHNP-BC Dana-Farber Cancer Institute Boston, MA
68 Overview Procuring PARP inhibitors for patients Understand adverse events associated with PARP inhibitors Dosing of PARP inhibitors How to manage adverse effects and discuss ways the oncology nurse can optimize therapy Understand ways nurses can improve adherence to PARP inhibitors Patient based cases
69 How Do I Procure PARP Inhibitors for My Patients? Rucaparib FDA approved for patients with advanced ovarian cancer who have BRCA gene mutations, either inherited (germline) or acquired (somatic) Two or more prior lines of chemotherapy Next generation sequencing-based companion diagnostic approved to test for deleterious mutations Olaparib FDA approved for patients with advanced ovarian cancer who have BRCA gene mutation (germline) Three or more prior lines of chemotherapy Multiplex PCR companion diagnostic approved to detect germline mutation Niraparib Maintenance treatment in recurrent ovarian, fallopian or primary peritoneal who have had a complete or partial response to platinum based therapy FDA Prescribing Information.
70 Somatic vs. Germline Mutations Somatic (Acquired) Mutations Occur in non-germline tissues Are not inherited Germline (Inherited) Mutations Present in egg or sperm Can be inherited from either parent Can cause cancer family syndrome Not Inheritable Inheritable Mutation only found in tumor Unaffected children Mutation in egg or sperm All cells affected in children Adapted from
71 Common Adverse Effects of PARP Inhibitors Fatigue Nausea and/or vomiting Decreased appetite Dysgeusia Abdominal pain Myelosuppression Changes in kidney function tests Shortness of breath Anemia Arthralgias/mylagias Rash Myelodysplastic syndrome (MDS) or Acute Myeloid Leukemia (AML)* FDA Prescribing Information. *Although rare, can be delayed and life threatening
72 Drug Specific Adverse Effects Rucaparib Constipation and/or diarrhea Changes in liver function tests Increased cholesterol levels Olaparib Indigestion/heartburn Rhinorrhea Pneumonitis Niraparib Palpitations Mucositis/dry mouth Increase in AST/ALT Urinary tract infections Hypertension Headache/dizziness FDA Prescribing Information.
73 Dosing Rucaparib 600 mg (two 300 mg tablets) taken orally twice daily Rucaparib is available in 300 mg and 200 mg tablets Olaparib 400 mg (eight 50 mg capsules) taken orally twice daily Niraparib 300 mg (three 100 mg capsules) taken once daily FDA Prescribing Information.
74 Other Important Safety Information Females who are able to become pregnant should use birth control during treatment and for six months after last dose. Do not breast feed during treatment and one month (niraparib/olaparib) or two weeks (rucaparib) after last dose. Avoid grapefruit, grapefruit juice and Seville oranges during treatment with olaparib. FDA Prescribing Information.
75 How Do I Manage Hematologic Adverse Effects Associated with PARP Inhibitors? Prior to initiating PARP inhibitor, prior chemotherapy adverse effects should have resolved to <Grade 1 Anemia Rule out other causes of anemia (iron deficiency) Transfuse as needed Dose interruption or dose reduction Thrombocytopenia First occurrence: Hold until platelets >100,000/µL. Resume at same or reduced dose Second occurrence: Hold until platelets >100,000/µL. Resume at reduced dose Discontinue if platelets have not returned to acceptable levels after 28 days Transfuse as needed Monitor closely for MDS FDA Prescribing Information; NCCN Anemia Guidelines Version
76 How Do I Manage Adverse Effects Associated with PARP Inhibitors? Monitor for MDS Check CBC/d prior to starting PARPi (olaparib, rucaparib) and monthly thereafter Check CBC/d weekly x 1 month, then monthly for the next 11 months and longer as indicated (niraparib) If hematological toxicities are noted: Interrupt PARP inhibitor and monitor blood counts weekly until Grade 1 or less If hematological profile recovers, consider restarting drug at a reduced dose If hematological profile has not recovered to Grade 1 or less after 4 weeks, refer to hematologist (bone marrow analysis, cytogenics) Discontinue drug if MDS/AML is confirmed FDA Prescribing Information.
77 How Do I Manage Adverse Effects Associated with PARP Inhibitors? Nausea/Vomiting Use PARP inhibitor sooner in disease course. GI symptoms often become more prominent later in disease course Consider starting PARP inhibitor at lower dose to allow patient to acclimate to drug. Increase dose as tolerated Prophylactic antiemetics 30 minutes prior to dosing Encourage small meal prior to dosing Consider dose reduction if not originally started at lower dose Try behavioral modifications GI Toxicity Small frequent meals Behavioral modifications (avoid carbohydrates, heavy meals) Work on effective bowel regimen
78 How Do I Manage Adverse Effects Associated with PARP Inhibitors? Pneumonitis Symptoms include cough, shortness of breath, fatigue and weight loss Discontinue drug Fatigue Monitor for anemia Encourage periods of rest and activity Maintain good nutrition Stay well hydrated Manage stress Consider dose interruption or dose reduction FDA Prescribing Information; NCCN Cancer-Related Fatigue Guidelines Version ;
79 Ensuring Patient Compliance Empower the patient Provide behavioral support Incorporate the medication regimen into daily regimen Adherence aids Medication boxes Patient alarms Patient drug diary Patient communication (Telephone calls, scheduled appointments) Manage side effects
80 Case Study 1: JG Ms. JG is a 65 year old woman with a BRCA germline mutation Diagnosed with a stage IIA papillary serous ovarian cancer. Underwent cytoreductive surgery followed by adjuvant carboplatin and paclitaxel x 6 cycles. December 2013 Diagnosed with recurrent disease. Underwent a secondary cytoreductive surgery followed by adjuvant carboplatin and gemcitabine x 6 cycles. Completed May July 2014 Enrolled in the SOLO2 trial evaluating olaparib 300 mg BID as maintenance therapy.
81 Case Study 1: JG August 26, 2014 Presented with Grade 3 anemia (Hct of 18) with low reticulocyte count. Leukopenia noted. Platelets normal. Olaparib interrupted 2 units of PRBC given Rule out other sources of anemia: Iron studies ordered Guaiac test done Hemolysis panel August 29, 2014 Repeat labs revealed anemia improved to Grade 2. Referred to Hematology to rule out aplastic anemia. Per Hematology, anemia related to olaparib.
82 Case Study 1: JG September 5, 2014 Patient presented with Grade 2 fatigue and Grade 1 anemia. Continued to hold olaparib September 23, 2014 Olaparib restarted at 300 mg BID CBC/d weekly October 16, 2014 Patient presented with Grade 2 fatigue and Grade 2 anemia (Hct 26.5). Olaparib discontinued given concern for potential MDS. November 2016 Rising CA 125, CT with recurrent disease
83 Case Study 2: DS DS is a 45 year old woman with a BRCA germline mutation and high grade serous adenocarcinoma. December 2013 Underwent a cytoreductive surgery in China. She subsequently received cycle 1 of carboplatin and paclitaxel but developed skin itching and declined further chemotherapy. She was managed with traditional Chinese medicine. May 2014 CT scan revealed recurrent disease. Received carboplatin and docetaxel x 4 cycles. August 2015 Repeat imaging revealed an isolated splenic lesion. She underwent an ex-lap, splenectomy with no residual disease. September 15, 2015 Initiated on single agent carboplatin x 6 given positive washings. November 2016 CA 125 elevated. CT revealed multiple new hepatic lesions. CT guided biopsy of liver mass. December 28, 2016 Initiated on olaparib 400 mg BID
84 Case Study 2: DS December 28, 2016 Initiated on olaparib 400 mg BID January 11, 2017 Patient presented with fatigue, nausea, vomiting, weakness, and abdominal pain Advised patient to hold drug x 3 days Restarted olaparib 400 mg BID Added prochlorperazine 10 mg 30 minutes prior to dosing Behavior modifications reviewed January 25, 2017 Patient presented with similar symptoms despite recommendations as above Dose reduced to 300 mg BID
85 Summary Patients with ovarian cancer often have multiple recurrences and many lines of therapy. All patients with ovarian cancer should have BRCA testing and genetic counseling (and certain patients with breast, prostate or pancreatic cancers). Patients with germline and somatic BRCA mutations may benefit from a PARPi with the goal of increased survival. There are three PARPi choices approved for recurrent ovarian cancer, all with separate indications. PARPi s are also being studied in breast, prostate, and pancreatic cancers. PARPi tolerability is achieved with early identification and assessment of hematological adverse effects and proactive prevention of nausea.
86
Optimizing DNA Damage Response- Targeting Therapies: Focus on Genetic Testing and Counseling
Disclaimer This slide deck in its original and unaltered format is for educational purposes and is current as of May 2017. The content and views presented in this educational activity are those of the
More informationUpdate on PARP inhibitors
Professor of Medicine Harvard Medical School Boston MA Update on PARP inhibitors Ursula Matulonis, M.D. Chief, Division of Gynecologic Oncology Brock-Wilson Family Chair Dana-Farber Cancer Institute History
More informationVirtual Journal Club. Ovarian Cancer. Reference Slides. Platinum-Sensitive Recurrent Ovarian Cancer: Making the Most of Emerging Targeted Therapies
Virtual Journal Club Ovarian Cancer Reference Slides Platinum-Sensitive Recurrent Ovarian Cancer: Making the Most of Emerging Targeted Therapies Mansoor R. Mirza, MD Copenhagen University Hospital Rigshospitalet
More informationPARP inhibitors for breast cancer
PARP inhibitors for breast cancer Mark Robson, MD Memorial Sloan Kettering Cancer Center Agenda Mechanism of action Clinical studies Resistance mechanisms Future directions Poly (ADP-ribose) Polymerases
More informationPARP Inhibitors: Patients Selection. Dr. Cristina Martin Lorente Hospital de la Santa Creu i Sant Pau Formigal, June 23th 2016
PARP Inhibitors: Patients Selection Dr. Cristina Martin Lorente Hospital de la Santa Creu i Sant Pau Formigal, June 23th 2016 OVARIAN CANCER (OC): MULTIPLES DISEASES Different types with different behaviour
More informationOverview and future horizons of PARP inhibitors in BRCAassociated. Judith Balmaña
Overview and future horizons of PARP inhibitors in BRCAassociated breast cancer Judith Balmaña PARP inhibitors: Mechanism of action Clinical development: Monotherapy In combination with chemotherapy Ongoing
More informationExpert Review: The Role of PARP Inhibition in the Treatment of Breast Cancer. Reference Slides
Expert Review: The Role of PARP Inhibition in the Treatment of Breast Cancer Reference Slides Overview BRCA Mutations and Breast Cancer Patients with BRCA mutations have an estimated 55% to 65% cumulative
More informationMedicina de precisión en cáncer de ovario: Determinación de BRCA germinal y somático
Medicina de precisión en cáncer de ovario: Determinación de BRCA germinal y somático Dra. Cristina Martin Lorente Hospital de la Santa Creu i Sant Pau. Barcelona Introduction Ovarian cancer is the fifth
More informationGenetic Testing For Ovarian Cancer: When, How And Who? Judith Balmaña, MD, PhD University Hospital Vall d Hebron Barcelona, Spain
Genetic Testing For Ovarian Cancer: When, How And Who? Judith Balmaña, MD, PhD University Hospital Vall d Hebron Barcelona, Spain Why Would We Consider Genetic Testing in Patients With Ovarian Cancer?
More informationDrug Niraparib Olaparib
Dear NCCN Value Pathway Committee, We are making this submission to provide information that we believe is relevant for developing NCCN Categories of Preference for the use of PARP inhibitors in recurrent
More informationObjectives: Describe poly-adp-ribose polymerase (PARP) inhibitors mechanism of action.
1 2 3 Role of PARP Inhibitors in Metastatic Breast Cancer Catie Chatowsky, PharmD PGY1 Pharmacy Resident Disclosure: I have nothing to disclose. Objectives: Describe poly-adp-ribose polymerase (PARP) inhibitors
More informationLearning Objectives. Page 1
Learning Objectives 1. Outline the role of the DNA damage response (DDR) pathway in tumor suppression and describe how mutations in DDR genes lead to tumor proliferation. 2. Explore recent advances in
More informationUpdate on PARP inhibitors: opportunities and challenges in cancer therapy
Update on PARP inhibitors: opportunities and challenges in cancer therapy Vanda Salutari Unità di Ginecologia Oncologica Fondazione Policlinico Universitario A. Gemelli vanda.salutari@policlinicogemelli.it
More informationOvarian Cancer: Implications for the Pharmacist
Ovarian Cancer: Implications for the Pharmacist Megan May, Pharm.D., BCOP Objectives Describe the etiology and pathophysiology of ovarian cancer Outline the efficacy and safety of treatment options for
More informationGenetic Testing Today: What Genes Can Tell Us. Living Beyond Breast Cancer Conference Kara N. Maxwell, MD, PhD University of Pennsylvania
Genetic Testing Today: What Genes Can Tell Us Living Beyond Breast Cancer Conference Kara N. Maxwell, MD, PhD University of Pennsylvania Overview of talk PART 1: Overview of Genetics PART 2: BRCA1/2 PART
More informationRicombinazione omologa nel carcinoma ovarico: BRCA e oltre. F. Raspagliesi MD
Ricombinazione omologa nel carcinoma ovarico: BRCA e oltre F. Raspagliesi MD raspagliesi@istitutotumori.mi.it BRCA molecular signature in ovarian cancer In a pooled analysis of 26 observational studies
More informationRubraca (rucaparib) Approved in the U.S. as Maintenance Treatment of Recurrent Ovarian Cancer
Rubraca (rucaparib) Approved in the U.S. as Maintenance Treatment of Recurrent Ovarian Cancer Rubraca is now indicated as maintenance treatment for women with recurrent ovarian cancer who are in a complete
More informationPractical Guidance and Strategies for PARP Inhibition. Nicoletta Colombo, MD University of Milan-Bicocca European Institute of Oncology Milan, Italy
Practical Guidance and Strategies for PARP Inhibition Nicoletta Colombo, MD University of Milan-Bicocca European Institute of Oncology Milan, Italy Clinical Data Maintenance therapy : BRCA-mutated or all
More informationA New String to the Bow in the Treatment of Advanced Ovarian Cancer Bradley J. Monk, MD, FACS, FACOG
A New String to the Bow in the Treatment of Advanced Ovarian Cancer Bradley J. Monk, MD, FACS, FACOG Arizona Oncology (US Oncology Network) Professor, Gynecologic Oncology University of Arizona and Creighton
More informationManagement of BRCA Positive Breast Cancer. Archana Ganaraj, MD February 17, 2018 UPDATE ON WOMEN S HEALTH
Management of BRCA Positive Breast Cancer Archana Ganaraj, MD February 17, 2018 UPDATE ON WOMEN S HEALTH The number of American women who have lost their lives to breast cancer outstrips the total number
More informationLearning Objectives. Page 1
Learning Objectives 1) Analyze the main signaling pathways and key mechanisms in DNA damage repair and how deficiencies in these pathways can lead to tumor proliferation and growth. 2) Examine the pharmacology
More informationLynparza. Lynparza (olaparib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.52 Subject: Lynparza Page: 1 of 5 Last Review Date: March 16, 2018 Lynparza Description Lynparza (olaparib)
More informationAssessment and Management of Genetic Predisposition to Breast Cancer. Dr Munaza Ahmed Consultant Clinical Geneticist 2/7/18
Assessment and Management of Genetic Predisposition to Breast Cancer Dr Munaza Ahmed Consultant Clinical Geneticist 2/7/18 Overview The role of the Cancer Genetics team NICE guidelines for Familial Breast
More informationCENTENE PHARMACY AND THERAPEUTICS NEW DRUG REVIEW 1Q17 January February
BRAND NAME Rubraca GENERIC NAME rucaparib MANUFACTURER Clovis Oncology, Inc. DATE OF APPROVAL December 19, 2016 PRODUCT LAUNCH DATE December 19, 2016 REVIEW TYPE Review type 1 (RT1): New Drug Review Full
More informationKey Recommendations. Gynecologic management of women with inherited risk of gynecologic cancer
Gynecologic management of women with inherited risk of gynecologic cancer C. Bethan Powell MD Kaiser Permanente Northern California Gynecologic Oncology Program Lead, Kaiser Permanente Northern California
More informationHereditary Breast and Ovarian Cancer Rebecca Sutphen, MD, FACMG
Hereditary Breast and Ovarian Cancer 2015 Rebecca Sutphen, MD, FACMG Among a consecutive series of 11,159 women requesting BRCA testing over one year, 3874 responded to a mailed survey. Most respondents
More informationDieta Brandsma, Department of Neuro-oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
What is hot in breast cancer brain metastases? Dieta Brandsma, Department of Neuro-oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands 8th Annual Brain Metastases Research and Emerging Therapy
More information6/8/17. Genetics 101. Professor, College of Medicine. President & Chief Medical Officer. Hereditary Breast and Ovarian Cancer 2017
Genetics 101 Hereditary Breast and Ovarian Cancer 2017 Rebecca Sutphen, MD, FACMG Professor, College of Medicine President & Chief Medical Officer INVASIVE CANCER GENETICALLY ALTERED CELL HYPERPLASIA DYSPLASIA
More information2/21/2016. Cancer Precision Medicine: A Primer. Ovarian Cancer Statistics and Standard of Care in 2015 OUTLINE. Background
Cancer Precision Medicine: A Primer Rebecca C. Arend, MD Division of Gyn Oncology OUTLINE Background Where we are Where we have been Where we are going Targeted Therapy in Ovarian Cancer How to Individualized
More informationCarrier Frequency. Breast Cancer and Treatment Options in Patients with BRCA1/2 mutations. Olivia Pagani On behalf of Bella Kaufman
Breast Cancer and Treatment Options in Patients with BRCA1/2 mutations Olivia Pagani On behalf of Bella Kaufman Carrier Frequency Prevalence of an altered disease gene in a given population 1 Background
More informationBreast Cancer and Treatment Options in Patients with BRCA1/2 mutations. Olivia Pagani On behalf of Bella Kaufman
Breast Cancer and Treatment Options in Patients with BRCA1/2 mutations Olivia Pagani On behalf of Bella Kaufman Carrier Frequency Prevalence of an altered disease gene in a given population Background
More informationRecrui ng now. Could you help by joining this study?
Pancrea c cancer POLO study Recrui ng now AstraZeneca is looking for people with BRCA-mutated metasta c pancrea c cancer to join POLO, a clinical study to help scien sts find be er treatments for this disease
More informationInhibidores de PARP en cáncer de ovario
Inhibidores de PARP en cáncer de ovario Ma Pilar Barretina Ginesta Servicio Oncología Médica Hospital Universitari Dr. J. Trueta Institut Català d Oncologia Coordinación científica: Dr. Fernando Rivera
More informationInhibidores de PARP Una realidad? dónde y cuando?
Inhibidores de PARP Una realidad? dónde y cuando? Alberto Ocana Hospital Universitario Albacete Centro Regional Investigaciones Biomédicas CIC-Salamanca DNA repair mechanisms DNA is continually exposed
More informationLynparza. Lynparza (olaparib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.52 Subject: Lynparza Page: 1 of 4 Last Review Date: September 15, 2017 Lynparza Description Lynparza
More informationSOLO-1. Dott.ssa Elisabetta Sanna U.O.C. Ginecologia Oncologica- AOB Cagliari Direttore: Dott. Antonio Macciò
SOLO-1 maintenance therapy in patients with newly diagnosed advanced ovarian cancer following platinum-based chemotherapy Dott.ssa Elisabetta Sanna U.O.C. Ginecologia Oncologica- AOB Cagliari Direttore:
More informationTriple-Negative Breast Cancer
June 2017 Triple-Negative Breast Cancer Amir Sonnenblick, MD, PhD Sharett institute of oncology Hadassah-Hebrew university medical center, Jerusalem, Israel This presentation is the intellectual property
More informationClinical Research on PARP Inhibitors and Triple-Negative Breast Cancer (TNBC)
Clinical Research on PARP Inhibitors and Triple-Negative Breast Cancer (TNBC) Eric P Winer, MD Disclosures for Eric P Winer, MD No real or apparent conflicts of interest to disclose Key Topics: PARP and
More informationDr. Josep M. Del Campo Clínica Diagonal. Barcelona
Dr. Josep M. Del Campo Clínica Diagonal. Barcelona Nuevas Oportunidades en Cáncer de Ovario Cancer de Ovario: Es una enfermedad única? Cáncer de Ovario: Tratamiento actual Tratamiento inicial: sin cambios
More informationImportanza del test genetico nel carcinoma mammario ed ovarico
Importanza del test genetico nel carcinoma mammario ed ovarico Lorena Incorvaia Azienda Ospedaliera Universitaria Policlinco «P.Giaccone» Palermo UOC Oncologia Medica Ovarian Cancer Breast Cancer The range
More informationTriple Negative Breast cancer New treatment options arenowhere?
Triple Negative Breast cancer New treatment options arenowhere? Ofer Rotem, M.D., B.Sc. Breast Unit, Davidoff center Rabin Medical center October 2017 Case 6/2013 - M.D., 38 years old woman, healthy, no
More informationBRCAplus. genetic testing for hereditary breast cancer
BRCAplus genetic testing for hereditary breast cancer Developed in collaboration with Fox Chase Cancer Center and the Arcadia University Genetic Counseling Program. Causes of Hereditary Breast Cancer familial
More informationUpdates in Cancer Genetics & Genomics
Updates in Cancer Genetics & Genomics Jennifer R. Klemp, PhD, MPH, MA Associate Professor of Medicine, Division of Clinical Oncology Director, Cancer Survivorship Co-Program Leader, Cancer Prevention and
More informationBrian T Burgess, DO, PhD, GYN Oncology Fellow Rachel W. Miller, MD, GYN Oncology
Brian T Burgess, DO, PhD, GYN Oncology Fellow Rachel W. Miller, MD, GYN Oncology Epithelial Ovarian Cancer - Standard Current Treatment: Surgery with De-bulking + Platinum-Taxane based Chemotherapy - No
More informationCurrent Medical Oncology Approaches to Gynecologic Cancers. Mihaela Cristea, MD Associate Professor Medical Oncology
Current Medical Oncology Approaches to Gynecologic Cancers Mihaela Cristea, MD Associate Professor Medical Oncology Nothing to disclose DISCLOSURE Ovarian Cancer Objectives: a. To discuss new FDA approved
More informationGermline Genetic Testing for Breast Cancer Risk
Kathmandu, Bir Hospital visit, August 2018 Germline Genetic Testing for Breast Cancer Risk Evidence-based Genetic Screening Rodney J. Scott Demography in New South Wales (total population ~ 7,000,000)
More informationDisclosure. Gynecologic Cancer Genetics. Audience response. Audience response. What was the result? 47%
Disclosure Cancer Genetics I have served as a moderator for an advisory board to Genentech Lee-may Chen, M.D. Professor Department of Obstetrics, Gynecology, & Reproductive Sciences UCSF Obstetrics and
More informationGenetic Panel Testing and Implications for Cancer Care
Genetic Panel Testing and Implications for Cancer Care Dana Zakalik, M.D. Nancy and James Grosfeld Cancer Genetics Center Professor, OUWB Medical School MCC Board of Directors Meeting September 28, 2016
More informationTreatment options in patients with early breast cancer and BRCAmutations or family history of cancer
PHARMACOTHERAPY 239 Treatment options in patients with early breast cancer and BRCAmutations or family history of cancer M-D. t Kint de Roodenbeke, MD 1, L. Buisserer, MD, PhD 2, M. Piccart-Gebhart, MD,
More informationPost-ASCO 2017 Cancer du sein Triple Négatif
Post-ASCO 217 Cancer du sein Triple Négatif A.Ladjeroud, K.Bouzid Centre Pierre et Marie Curie- Alger Oran, 3 Septembre 217 Phase III Investigation of Neoadjuvant Carboplatin ± Veliparib in Combination
More informationTable Selected Clinical Trials of Anti-Angiogenesis Therapy in Gynecologic Malignancies
Table Selected Clinical Trials of Anti-Angiogenesis Therapy in Gynecologic Malignancies Uterus Study N Eligibility Regimen RR (No. of Responses) Median OS Grade 3/4 Toxicities Nimeiri et al[42] Total:
More informationNCCP Chemotherapy Regimen. Olaparib Monotherapy
Olaparib INDICATIONS FOR USE: INDICATION ICD10 Regimen Code *Reimbursement Indicator Maintenance treatment of adult patients with platinum -sensitive relapsed BRCAmutated (germline and/or somatic) - high
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Lynparza) Reference Number: CP.PHAR.360 Effective Date: 10.03.17 Last Review Date: 02.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this
More informationPROSTATE CANCER HORMONE THERAPY AND BEYOND. Przemyslaw Twardowski MD Professor of Oncology Department of Urologic Oncology John Wayne Cancer Institute
PROSTATE CANCER HORMONE THERAPY AND BEYOND Przemyslaw Twardowski MD Professor of Oncology Department of Urologic Oncology John Wayne Cancer Institute Disclosures I am a Consultant for Bayer and Sanofi-Aventis
More informationWHAT IS A GENE? CHROMOSOME DNA PROTEIN. A gene is made up of DNA. It carries instructions to make proteins.
WHAT IS A GENE? CHROMOSOME E GEN DNA A gene is made up of DNA. It carries instructions to make proteins. The proteins have specific jobs that help your body work normally. PROTEIN 1 WHAT HAPPENS WHEN THERE
More informationPARP inibitori nel trattamento del carcinoma mammario metastatico: recenti successi e prospettive future.
PARP inibitori nel trattamento del carcinoma mammario metastatico: recenti successi e prospettive future. Dr.ssa Angela Toss Centro Oncologico Modenese Università di Modena e Reggio Emilia MECHANISMS OF
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Olaparib (Lynparza) for Ovarian Cancer September 29, 2016
pan-canadian Oncology Drug Review Final Clinical Guidance Report Olaparib (Lynparza) for Ovarian Cancer September 29, 2016 DISCLAIMER Not a Substitute for Professional Advice This report is primarily intended
More informationAbstract # 1503: Predisposing germline mutations in high grade ER+ HER2- breast cancer patients diagnosed age < 50
Abstract # 1503: Predisposing germline mutations in high grade ER+ HER2- breast cancer patients diagnosed age < 50 Garber JE 1, Tung NM 2, Elkin EP 3, Allen BA 3, Singh NA 3, Wenstrup R 3, Hartman AR 3,
More informationDNA Damage Response analyst science event
DNA Damage Response analyst science event Mene Pangalos, EVP, Innovative Medicines & Early Development and Business Development Klaus Edvardsen, Vice President, Oncology Clinical, Global Medicines Development
More informationGynecologic Cancers are many diseases. Gynecologic Cancers in the Age of Precision Medicine Advances in Internal Medicine. Speaker Disclosure:
Gynecologic Cancer Care in the Age of Precision Medicine Gynecologic Cancers in the Age of Precision Medicine Advances in Internal Medicine Lee-may Chen, MD Department of Obstetrics, Gynecology & Reproductive
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Olaparib (Lynparza) for Ovarian Cancer - Resubmission September 20, 2017
pan-canadian Oncology Drug Review Final Clinical Guidance Report Olaparib (Lynparza) for Ovarian Cancer - Resubmission September 20, 2017 DISCLAIMER Not a Substitute for Professional Advice This report
More informationProgress Update June 2017 Lay Summary Funding: $6,000,000 Grant Funded: July 2015 Dream Team Members Dream Team Leader:
SU2C -Ovarian Cancer Research Fund Alliance-National Ovarian Cancer Coalition Dream Team Translational Research Grant: DNA Repair Therapies for Ovarian Cancer AND SU2C Catalyst Merck-Supported Supplemental
More informationGenetics & Precision Medicine Cancer Care
Genetics & Precision Medicine Cancer Care Johnathan M. Lancaster, MD PhD Chief Medical Officer Myriad Genetics Copyright 2015 Myriad Genetics, Inc., all rights reserved. www.myriad.com. Precision Medicine
More informationMyriad Genetics mychoice HRD Update 06/30/2016
Myriad Genetics mychoice HRD Update 06/30/2016 1 Forward Looking Statements Some of the information presented here today may contain projections or other forward-looking statements regarding future events
More informationTriple Negative Breast Cancer
GASCO 2016 San Antonio Breast Cancer Symposium Review Triple Negative Breast Cancer Amelia Zelnak, MD, MSc Atlanta Cancer Care Northside Hospital Cancer Institute Disclosures: consultant for Novartis,
More informationBRCA2 gene. Associated Syndrome Name: Hereditary Breast and Ovarian Cancer syndrome (HBOC) BRCA2 Summary Cancer Risk Table. BRCA2 gene Overview
BRCA gene Associated Syndrome Name: Hereditary Breast and Cancer syndrome (HBOC) BRCA Summary Cancer Risk Table Male Breast GENETIC RISK Female Breast Elevated Risk Elevated Risk BRCA gene Overview Hereditary
More informationLYNPARZA (olaparib) oral capsule and tablet
LYNPARZA (olaparib) oral capsule and tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationTREATMENT FOR RELAPSING PLATINUM SENSITIVE EPITHELIAL OVARIAN CANCER
TREATMENT FOR RELAPSING PLATINUM SENSITIVE EPITHELIAL OVARIAN CANCER Sandro Pignata, MD, PhD Sabrina Chiara Cecere, MD Uro-Gynecological Department, Division of Medical Oncology, IRCCS National Cancer
More informationGynecologic Cancers are many diseases. Speaker Disclosure: Gynecologic Cancer Care in the Age of Precision Medicine. Controversies in Women s Health
Gynecologic Cancer Care in the Age of Precision Medicine Gynecologic Cancers in the Age of Precision Medicine Controversies in Women s Health Lee-may Chen, MD Department of Obstetrics, Gynecology & Reproductive
More informationHereditary Cancer Risk Assessment for Gynecological Cancers. FarrNezhatMD.com
Hereditary Cancer Risk Assessment for Gynecological Cancers FarrNezhatMD.com Image credit: PLOS blogs 5-10% hereditary 10-20% 70-80% sporadic Genetic Changes and Cancer Cancer begins with a genetic
More informationWHAT IS A GENE? CHROMOSOME DNA PROTEIN. A gene is made up of DNA. It carries instructions to make proteins.
WHAT IS A GENE? CHROMOSOME GENE DNA A gene is made up of DNA. It carries instructions to make proteins. The proteins have specific jobs that help your body work normally. PROTEIN 1 WHAT HAPPENS WHEN THERE
More informationGenetics of Breast and Ovarian Cancer: Risk Assessment, Screening, and Risk Reduction
Genetics of Breast and Ovarian Cancer: Risk Assessment, Screening, and Risk Reduction Forum INCA-ASCO sobre Cancer Hereditario e Predisposicao Genetica ao Cancer Jeffrey N. Weitzel, M.D. Professor of Oncology
More informationPredictive and Diagnostic Testing for Cancer in Women. Aparna Rajadhyaksha MD
Predictive and Diagnostic Testing for Cancer in Women Aparna Rajadhyaksha MD Hereditary Cancer s in Women BRCA1 &2 Other Breast Cancer Genes Li Fraumeni PTEN CHEK2 BRCA1&2 t BRCA1 is part of a complex
More informationFeasibility of Clinical Trial Implementation Genetically Eligible Prostate Cancer Patients Oliver Sartor, MD Cathryn E, Garvey, MS December 3, 2015
Feasibility of Clinical Trial Implementation Genetically Eligible Prostate Cancer Patients Oliver Sartor, MD Cathryn E, Garvey, MS December 3, 2015 Study Name Feasibility of Patient Population for proposed
More informationIdentification of patients suggestive of hereditary breast and ovarian cancer syndrome that warrants further professional evaluation.
Allina Breast Program Committee Consensus Guidelines These guidelines apply to clinical interventions that have well-documented outcomes, but whose outcomes are not clearly desirable to all patients Identification
More informationTriple Negative Breast Cancer: Part 2 A Medical Update
Triple Negative Breast Cancer: Part 2 A Medical Update April 29, 2015 Tiffany A. Traina, MD Breast Medicine Service Memorial Sloan Kettering Cancer Center Weill Cornell Medical College Overview What is
More informationUnderstanding Your Genetic Test Result. Positive for a Deleterious Mutation or Suspected Deleterious
Understanding Your Genetic Test Result Positive for a Deleterious Mutation or Suspected Deleterious This workbook is designed to help you understand the results of your genetic test and is best reviewed
More informationMP Genetic Testing for BRCA1 or BRCA2 for Hereditary Breast/Ovarian Cancer Syndrome and Other High-Risk Cancers
Medical Policy MP 2.04.02 Genetic Testing for BRCA1 or BRCA2 for Hereditary Breast/Ovarian Cancer Syndrome and Other High-Risk BCBSA Ref. Policy: 2.04.02 Last Review: 11/15/2018 Effective Date: 02/15/2019
More informationGOG212: Taxane Maintenance
GOG212: Taxane Maintenance Epithelial Ovarian or Primary Peritoneal Cancer Optimal or Suboptimal Cytoreduction Clinical C with normal CA125, no symptoms, normal CT Primary Carboplatin and Paclitaxel (or
More informationHDAC Inhibitors and PARP inhibitors. Suresh Ramalingam, MD Associate Professor Chief of Thoracic Oncology Emory University School of Medicine
HDAC Inhibitors and PARP inhibitors Suresh Ramalingam, MD Associate Professor Chief of Thoracic Oncology Emory University School of Medicine Histone Acetylation HAT Ac Ac Ac Ac HDAC Ac Ac Ac Ac mrna DACs
More informationOvarian Cancer: It s Personal
Ovarian Cancer: It s Personal Review ovarian cancer: Incidence, origin, and management Discuss genetic testing: Who, why and what? Review current treatments for ovarian cancer Enhance understanding of
More informationEvaluation of BRCA1/2 and homologous recombination defects in ovarian cancer and impact on clinical outcomes
Evaluation of BRCA1/2 and homologous recombination defects in ovarian cancer and impact on clinical outcomes Melinda S. Yates, PhD Department of Gynecologic Oncology & Reproductive Medicine University
More informationThe next wave of successful drug therapy strategies in HER2-positive breast cancer. Hans Wildiers University Hospitals Leuven Belgium
The next wave of successful drug therapy strategies in HER2-positive breast cancer Hans Wildiers University Hospitals Leuven Belgium Trastuzumab in 1st Line significantly improved the prognosis of HER2-positive
More informationGASTRIC & PANCREATIC CANCER
GASTRIC & PANCREATIC CANCER ASCO HIGHLIGHTS 2005 Fadi Sami Farhat, MD Head of Hematology Oncology Division Hammoud Hospital University Medical Center Saida Lebanon Tel: +961 3 753 155 E-Mail: drfadi@drfadi.org
More informationPoly ADP-Ribose Polymerase (PARP) Inhibitors for Ovarian Cancer: Effectiveness & Value. Evidence Report. August 30, 2017.
Poly ADP-Ribose Polymerase (PARP) Inhibitors for Ovarian Cancer: Effectiveness & Value Evidence Report August 30, 2017 Prepared for Institute for Clinical and Economic Review, 2017 ICER Staff/Consultants
More informationModelling cancer risk predictions:clinical practice perspective.
Modelling cancer risk predictions:clinical practice perspective. Judith Balmaña, MD, PhD Familial Cancer Program Medical Oncology Department Hospital Vall d Hebron, VHIO Barcelona, Spain It is very difficult
More informationCASE STUDY. Mutation-Specific Testing: Eligibility for PARP Inhibitor Therapy Established. Introduction. Patient Profile.
CASE STUDY Mutation-Specific Testing: Eligibility for PARP Introduction Genetic testing is an emergent diagnostic technique that can provide specific and actionable inputs to the management of cancer therapy.
More informationUnderstanding Your Genetic Test Result. Positive for a Deleterious Mutation or Suspected Deleterious
Understanding Your Genetic Test Result Positive for a Deleterious Mutation or Suspected Deleterious This workbook is designed to help you understand the results of your genetic test and is best reviewed
More informationPatient-Centric Science-Based Performance-Driven
Patient-Centric Science-Based Performance-Driven Cowen & Co. 38 th Annual Health Care Conference Michael Pehl, President and Chief Executive Officer March 12, 2018 Forward-Looking Statements This presentation,
More informationNuevas estrategias de tratamiento en tumores con mutaciones de BRCA
Nuevas estrategias de tratamiento en tumores con mutaciones de BRCA Emilio Alba UGCI Oncología Hospital Universitario Regional y Virgen de la Victoria Facultad de Medicina. Málaga IBIMA ÍNDICE DE LA PRESENTACIÓN
More informationGYNplus: A Genetic Test for Hereditary Ovarian and/or Uterine Cancer
GYNplus: A Genetic Test for Hereditary Ovarian and/or Uterine Cancer Causes of Hereditary Ovarian and Uterine Cancer uterine cancer ovarian cancer Sporadic 75-90% Sporadic 70-80% Hereditary, 5% Lynch syndrome
More informationPoly ADP-Ribose Polymerase (PARP) Inhibitors for Ovarian Cancer: Effectiveness and Value. Final Evidence Report. September 28, 2017.
Poly ADP-Ribose Polymerase (PARP) Inhibitors for Ovarian Cancer: Effectiveness and Value Final Evidence Report September 28, 2017 Prepared for Institute for Clinical and Economic Review, 2017 ICER Staff/Consultants
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
BRCA1 and BRCA2 Testing Page 1 of 33 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: BRCA1 and BRCA2 Testing Pre-Determination of Services IS REQUIRED by the Member
More informationGenetic Testing: who, what, why?
Genetic Testing: who, what, why? Gina Westhoff MD LMG Gynecologic Oncology March 16, 2019 Disclosures Speaker for Merck (unrelated to today s topic) Objectives Determine who should undergo genetic risk
More informationBiomarker for Response and Resistance in Ovarian Cancer
2016 대한부인종양학회제 31 차춘계학술대회 New Trends in Translational Research Biomarker for Response and Resistance in Ovarian Cancer Shin-Wha Lee, M.D., Ph.D. Department of Obstetrics and Gynecology ASAN Medical Center
More informationESMO SUMMIT AFRICA. Latest evidence and current standard of care in advanced ovarian cancer. C.Sessa. Cape Town February 2018
ESMO SUMMIT AFRICA Latest evidence and current standard of care in advanced ovarian cancer C.Sessa IOSI, Bellinzona, CH Cape Town 14-16 February 2018 CONFLICT OF INTEREST DISCLOSURE None Ovarian carcinoma
More informationAssessing Your Patient s Breast Cancer Risk: Is Genetic Testing Necessary?
May 16, 2016 Assessing Your Patient s Breast Cancer Risk: Is Genetic Testing Necessary? Presenter: Emily Kuchinsky, MS, CGC 1 Experiences with Genetic Testing Adverse Events in Cancer Genetic Testing:
More informationTargeted Molecular Therapy Gynaecological Cancer Where are we now?
Targeted Molecular Therapy Gynaecological Cancer Where are we now? 0 T O M D E G R E V E S U B - S P E C I A LT Y F E L L O W G Y N A E C O L O G I C A L O N C O L O G Y U N I V E R S I T Y O F P R E T
More information